vs

Side-by-side financial comparison of Ingevity Corp (NGVT) and Oncology Institute, Inc. (TOI). Click either name above to swap in a different company.

Ingevity Corp is the larger business by last-quarter revenue ($185.4M vs $142.0M, roughly 1.3× Oncology Institute, Inc.). Oncology Institute, Inc. runs the higher net margin — -5.3% vs -45.6%, a 40.3% gap on every dollar of revenue. On growth, Oncology Institute, Inc. posted the faster year-over-year revenue change (41.6% vs 36.7%). Ingevity Corp produced more free cash flow last quarter ($73.5M vs $2.2M). Over the past eight quarters, Oncology Institute, Inc.'s revenue compounded faster (22.5% CAGR vs -26.2%).

Ingevity Corp is a global specialty chemicals and advanced materials manufacturer. It produces high-performance carbon materials, pavement preservation solutions, and specialty chemicals, serving automotive emissions control, industrial purification, road infrastructure, and agricultural input markets across North America, Europe, and Asia Pacific.

Oncology Institute, Inc. is a specialized healthcare enterprise focused on delivering patient-centric, evidence-based oncology care services, including advanced treatment regimens, clinical trial access, and supportive care programs. It primarily operates across the United States, serving patients with diverse cancer diagnoses and partnering with care teams to improve treatment outcomes.

NGVT vs TOI — Head-to-Head

Bigger by revenue
NGVT
NGVT
1.3× larger
NGVT
$185.4M
$142.0M
TOI
Growing faster (revenue YoY)
TOI
TOI
+4.9% gap
TOI
41.6%
36.7%
NGVT
Higher net margin
TOI
TOI
40.3% more per $
TOI
-5.3%
-45.6%
NGVT
More free cash flow
NGVT
NGVT
$71.3M more FCF
NGVT
$73.5M
$2.2M
TOI
Faster 2-yr revenue CAGR
TOI
TOI
Annualised
TOI
22.5%
-26.2%
NGVT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
NGVT
NGVT
TOI
TOI
Revenue
$185.4M
$142.0M
Net Profit
$-84.6M
$-7.5M
Gross Margin
41.2%
Operating Margin
-47.7%
-4.9%
Net Margin
-45.6%
-5.3%
Revenue YoY
36.7%
41.6%
Net Profit YoY
-609.6%
43.0%
EPS (diluted)
$-2.33
$-0.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NGVT
NGVT
TOI
TOI
Q4 25
$185.4M
$142.0M
Q3 25
$333.1M
$136.6M
Q2 25
$365.1M
$119.8M
Q1 25
$284.0M
$104.4M
Q4 24
$135.6M
$100.3M
Q3 24
$333.8M
$99.9M
Q2 24
$390.6M
$98.6M
Q1 24
$340.1M
$94.7M
Net Profit
NGVT
NGVT
TOI
TOI
Q4 25
$-84.6M
$-7.5M
Q3 25
$43.5M
$-16.5M
Q2 25
$-146.5M
$-17.0M
Q1 25
$20.5M
$-19.6M
Q4 24
$16.6M
$-13.2M
Q3 24
$-107.2M
$-16.1M
Q2 24
$-283.7M
$-15.5M
Q1 24
$-56.0M
$-19.9M
Gross Margin
NGVT
NGVT
TOI
TOI
Q4 25
41.2%
Q3 25
40.2%
Q2 25
37.8%
Q1 25
39.9%
Q4 24
81.3%
Q3 24
39.4%
Q2 24
31.5%
Q1 24
29.3%
Operating Margin
NGVT
NGVT
TOI
TOI
Q4 25
-47.7%
-4.9%
Q3 25
18.7%
-5.9%
Q2 25
-39.1%
-9.4%
Q1 25
9.4%
-9.5%
Q4 24
-11.9%
Q3 24
33.0%
-13.9%
Q2 24
25.9%
-16.6%
Q1 24
22.6%
-19.0%
Net Margin
NGVT
NGVT
TOI
TOI
Q4 25
-45.6%
-5.3%
Q3 25
13.1%
-12.1%
Q2 25
-40.1%
-14.2%
Q1 25
7.2%
-18.8%
Q4 24
12.2%
-13.1%
Q3 24
-32.1%
-16.1%
Q2 24
-72.6%
-15.7%
Q1 24
-16.5%
-21.0%
EPS (diluted)
NGVT
NGVT
TOI
TOI
Q4 25
$-2.33
$-0.04
Q3 25
$1.18
$-0.14
Q2 25
$-4.02
$-0.15
Q1 25
$0.56
$-0.21
Q4 24
$0.44
$-0.14
Q3 24
$-2.94
$-0.18
Q2 24
$-7.81
$-0.17
Q1 24
$-1.54
$-0.22

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NGVT
NGVT
TOI
TOI
Cash + ST InvestmentsLiquidity on hand
$78.1M
Total DebtLower is stronger
$1.2B
Stockholders' EquityBook value
$29.7M
$-15.7M
Total Assets
$1.7B
$164.7M
Debt / EquityLower = less leverage
39.10×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NGVT
NGVT
TOI
TOI
Q4 25
$78.1M
Q3 25
$83.4M
Q2 25
$76.9M
Q1 25
$71.5M
Q4 24
$68.0M
Q3 24
$135.5M
Q2 24
$107.4M
$9.9M
Q1 24
$88.5M
$29.8M
Total Debt
NGVT
NGVT
TOI
TOI
Q4 25
$1.2B
Q3 25
$1.2B
Q2 25
$1.2B
Q1 25
$1.3B
Q4 24
$1.3B
Q3 24
$1.4B
Q2 24
$1.4B
Q1 24
$1.4B
Stockholders' Equity
NGVT
NGVT
TOI
TOI
Q4 25
$29.7M
$-15.7M
Q3 25
$138.1M
$-12.3M
Q2 25
$120.7M
$-9.0M
Q1 25
$234.6M
$5.1M
Q4 24
$195.2M
$3.6M
Q3 24
$214.5M
$15.5M
Q2 24
$284.8M
$29.2M
Q1 24
$568.2M
$41.3M
Total Assets
NGVT
NGVT
TOI
TOI
Q4 25
$1.7B
$164.7M
Q3 25
$1.8B
$163.6M
Q2 25
$1.9B
$159.8M
Q1 25
$2.1B
$164.0M
Q4 24
$2.0B
$172.7M
Q3 24
$2.2B
$179.2M
Q2 24
$2.3B
$179.6M
Q1 24
$2.6B
$204.5M
Debt / Equity
NGVT
NGVT
TOI
TOI
Q4 25
39.10×
Q3 25
8.39×
Q2 25
10.24×
Q1 25
5.68×
Q4 24
6.86×
Q3 24
6.52×
Q2 24
4.92×
Q1 24
2.48×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NGVT
NGVT
TOI
TOI
Operating Cash FlowLast quarter
$97.1M
$3.2M
Free Cash FlowOCF − Capex
$73.5M
$2.2M
FCF MarginFCF / Revenue
39.6%
1.5%
Capex IntensityCapex / Revenue
12.7%
0.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$273.5M
$-27.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NGVT
NGVT
TOI
TOI
Q4 25
$97.1M
$3.2M
Q3 25
$129.7M
$-12.6M
Q2 25
$79.0M
$-10.2M
Q1 25
$25.4M
$-5.0M
Q4 24
$64.5M
$4.2M
Q3 24
$46.5M
$819.0K
Q2 24
$29.7M
$-15.7M
Q1 24
$-12.1M
$-15.9M
Free Cash Flow
NGVT
NGVT
TOI
TOI
Q4 25
$73.5M
$2.2M
Q3 25
$117.8M
$-13.2M
Q2 25
$66.8M
$-11.4M
Q1 25
$15.4M
$-5.3M
Q4 24
$39.6M
$2.4M
Q3 24
$28.5M
$417.0K
Q2 24
$11.6M
$-17.5M
Q1 24
$-28.7M
$-16.5M
FCF Margin
NGVT
NGVT
TOI
TOI
Q4 25
39.6%
1.5%
Q3 25
35.4%
-9.7%
Q2 25
18.3%
-9.5%
Q1 25
5.4%
-5.1%
Q4 24
29.2%
2.4%
Q3 24
8.5%
0.4%
Q2 24
3.0%
-17.7%
Q1 24
-8.4%
-17.4%
Capex Intensity
NGVT
NGVT
TOI
TOI
Q4 25
12.7%
0.7%
Q3 25
3.6%
0.4%
Q2 25
3.3%
1.0%
Q1 25
3.5%
0.3%
Q4 24
18.4%
1.8%
Q3 24
5.4%
0.4%
Q2 24
4.6%
1.9%
Q1 24
4.9%
0.6%
Cash Conversion
NGVT
NGVT
TOI
TOI
Q4 25
Q3 25
2.98×
Q2 25
Q1 25
1.24×
Q4 24
3.89×
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

NGVT
NGVT

Performance Materials$151.2M82%
Advanced Polymer Technologies Segment$36.5M20%

TOI
TOI

Other$82.1M58%
Fee For Service$36.3M26%
Capitated Revenue$23.6M17%

Related Comparisons